Accelerating Science: How to cure the incurable with cell and gene therapy

Resolution ctDx FIRST Assay by Agilent Technologies

Manufacturer Agilent Technologies  |  Available Worldwide

Agilent Resolution ctDx FIRST is a liquid biopsy NGS assay optimized for cancer genomic profiling. ctDx FIRST is an FDA approved companion diagnostic to KRAZATI™ (adagrasib) for the detection of KRAS G12C in non-small cell lung cancer (NSCLC) and provides tumor mutation profiling for single nucleotide variants (SNVs) and deletions in the EGFR gene.


Resolution ctDx FIRST Assay by Agilent Technologies product image
Resolution ctDx FIRST Assay
Request Pricing

Receive your quote directly from the manufacturer.



0 Scientists have reviewed this product


Write the First Review

No Reviews

Agilent Resolution ctDx FIRST is a liquid biopsy NGS assay optimized for cancer genomic profiling. ctDx FIRST is an FDA approved companion diagnostic to KRAZATI™ (adagrasib) for the detection of KRAS G12C in non-small cell lung cancer (NSCLC) and provides tumor mutation profiling for single nucleotide variants (SNVs) and deletions in the EGFR gene.

Additionally, the professional services portion of the test report (CLIA-validated, not FDA approved) includes comprehensive genomic profiling on 109 genes across 4 types of alterations: SNVs, insertions and deletions (indels), copy number amplifications (CNAs), and fusions.

Features:

  • All bullets below refer to the Professional Services Report Features (CLIA-validated, not FDA approved)
  • 109 genes associated with solid tumor malignancies
  • 103 genes with SNV/indel detection (64% of genes have full coding sequence (CDS) coverage)
  • 54 genes with copy number amplification detection
  • 13 genes with fusion detection (Note for NRTK3: Only fusions with ETV6 fusion partner are detected)
  • Covers guideline recommended genes for molecular targets in NSCLC
  • Integrated low-pass whole genome (LPWG